Skip to main content

Table 1 Comparison of baseline characteristics between treatment groups

From: A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease

Measurements Mean baseline pre-VSL#3® (n = 19) Mean baseline pre-placebo (n = 16) p value
Age (y) 57 ± 8 58 ± 7 0.96
Gender (male/female)b 15/4 13/3 0.91
Duration NAFLD (y)b 0.25 IQR 2.0 1.0 IQR 1.5 0.27
No. of T2DM (or IFG)b 15 11 0.61
No. of smokersb 2 2 0.94
Alcohol (units/wk)b 1 IQR 8 6 IQR 8 0.10
BMI (kg/m2)b 31.2 IQR 9.1 31.9 IQR 4.0 0.57
Waist circumference (cm) 112.2 ± 14.3 111.2 ± 10.7 0.81
Systolic BP (mmHg) 133 ± 13 135 ± 12 0.56
Diastolic BP (mmHg) 82 ± 8 82 ± 7 0.91
Total cholesterol (mmol/l) 4.51 ± 1.38 4.31 ± 0.85 0.61
HDL (mmol/l)b 0.98 IQR 0.35 0.95 IQR 0.54 0.66
LDL (mmo/l) 2.58 ± 1.18 2.42 ± 0.70 0.64
Triglycerides (mmol/l)b 1.80 IQR 0.45 1.80 IQR 1.27 0.73
HbA1c (mmol/mol)b 54 IQR 17 47 IQR 19 0.23
HOMA-IRb 1.6 IQR 1.7 3.0 IQR 1.8 0.04a
ALT (iu/L)b 43 IQR 56 51 IQR 30 0.96
AST (iu/L) 40 ± 16 40 ± 15 0.99
  1. ap < 0.05
  2. bMann Whitney U test for non-parametric data one missing value on LDL as triglyceride (> 4.5 mmol/l) was too high for LDL calculation